SCHEDULE: Armistice Capital Discloses 9.99% Stake in Artelo Biosciences

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 9.99% of Artelo Biosciences, Inc. common stock as of March 31, 2026.

Summary

• Armistice Capital, LLC and Steven Boyd collectively hold 235,823 shares of Artelo Biosciences, Inc. common stock.
• This holding represents 9.99% of the total class of securities.
• The filing is made under Schedule 13G, indicating passive investment.
• Armistice Capital, LLC is the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, may be deemed to beneficially own these shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a standard disclosure of a significant passive stake, providing information on ownership but not on the company's operational performance or future outlook.

Positives

• Armistice Capital has taken a significant passive stake (9.99%) in Artelo Biosciences, Inc., which could signal confidence in the company's future prospects.
• The filing indicates that the shares were acquired and are held in the ordinary course of business, not for the purpose of influencing control.

Negatives

• The Master Fund disclaims beneficial ownership of the shares due to its investment management agreement with Armistice Capital, which limits its voting and disposal powers.
• The filing does not provide details on the acquisition cost or strategy behind the investment.

Risks

• Potential for increased scrutiny from management or other shareholders due to the significant stake.
• Market volatility could impact the value of the investment.
• Changes in Artelo Biosciences' business performance or strategic direction could negatively affect the investment.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Artelo Biosciences. It is a disclosure of beneficial ownership by Armistice Capital.

Management Comments

• Armistice Capital, LLC is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings typically indicate a passive investment strategy by institutional investors. A 9.99% stake is a significant holding, often seen as a signal of conviction, but the 'ordinary course of business' certification suggests no immediate intent to influence control.

Stakeholder Impact

• Shareholders: The filing provides transparency on ownership structure, with Armistice Capital holding a notable passive stake.
• Management of Artelo Biosciences: May note the significant passive stake and its implications for shareholder base.
• Potential Investors: The disclosure may be of interest to those tracking institutional ownership in Artelo Biosciences.

Next Steps

• Armistice Capital will continue to hold its shares in Artelo Biosciences, Inc.
• Further amendments to this Schedule 13G will be filed if there are changes in beneficial ownership.

Key Dates

Keywords

Artelo Biosciences, Armistice Capital, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Management, Passive Stake